Trending...
- Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
- Bergey's Truck Centers Recognized in 2026 MACH Alliance Composable Impact Awards
- What Would you Do with Your Time if it Was Actually Money?
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 13, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) securities between May 11, 2020 and November 4, 2020, inclusive (the "Class Period").
Investors suffering losses on their bluebird investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for LentiGlobin for sickle cell disease in the second half of 2021.
On November 4, 2020, post-market, bluebird disclosed that it would delay its BLA submission to late 2022 due to "feedback" from the FDA that requires the Company to provide additional data "to demonstrate drug product comparability" for LentiGlobin for sickle cell disease, as well as "COVID-19 related shifts and contract manufacturing organization COVID-19 impacts."
More on The PennZone
On this news, bluebird's stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (2) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (3) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
If you purchased or otherwise acquired bluebird securities during the Class Period, you may move the Court no later than April 13, 2021 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Investors suffering losses on their bluebird investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for LentiGlobin for sickle cell disease in the second half of 2021.
On November 4, 2020, post-market, bluebird disclosed that it would delay its BLA submission to late 2022 due to "feedback" from the FDA that requires the Company to provide additional data "to demonstrate drug product comparability" for LentiGlobin for sickle cell disease, as well as "COVID-19 related shifts and contract manufacturing organization COVID-19 impacts."
More on The PennZone
- Inframark–Slater Joint Venture Selected to Manage Fulton County Wastewater Operations
- Cancun International Airport Reports Strong Start to Summer 2026 Travel Season
- Freedomtech Solutions Launches the World's First Pre‑Installed Agentic AI Server — Instant, Sovereign, Infrastructure‑Native Intelligence
- GitKraken Introduces Code Flow, a Framework for Software Development in the Agentic Era
- Nola Blue Records announces new album from The Anthony Paule Soul Orchestra featuring Willy Jordan
On this news, bluebird's stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (2) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (3) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
- RIGHT CARS Announces Landmark African Expansion Through Strategic Collaboration Agreement Across Eight Nations
- Kyle Schwarber Surprises Local Fan After Heartbreaking Loss
- Custom Woodworker Launches Updated Website
- Boston Industrial Solutions' Natron® 717N Series UV LED Ink Receives CPSIA Certification
- purelyIV Expands Mobile IV Therapy to Jackson, MI and Launches PlaqueX® IV Therapy
If you purchased or otherwise acquired bluebird securities during the Class Period, you may move the Court no later than April 13, 2021 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Filed Under: Business
0 Comments
Latest on The PennZone
- Haven Media Solutions Offers Web Design and PPC Services in Atlanta GA
- TREND Network Announces Miami Based Reality Series "Coming Up Miami" Premiering July 1
- Beemok Hospitality Collection And KLH Group Announce Preferred Partnership
- Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
- Dr. Stephen Shainbart Launches Expanded Mental Health Support for Anxiety and Depression in Toronto
- Equipment Leases, Inc. Launches Updated Family Office Equipment Financing Page
- The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
- Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
- $150+ Million Contracted Backlog, Strategic Acquisitions Adding Millions In Recurring Revenue, Improving Margins & A Clear Path Toward Profitability
- Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
- Bergey's Truck Centers Recognized in 2026 MACH Alliance Composable Impact Awards
- What Would you Do with Your Time if it Was Actually Money?
- Mr. Hospital Bed Showcases the Best Hospital Bed and Air Mattress for Bed Sores for 2026
- Traian TKD Tractari Auto Iasi: cum transporti legal la RAR o masina fara numere sau cu ITP expirat
- Mike Williams Golf Center Now Open at Georgia's Lanier Islands Resort
- Appliance EMT Launches June "Summer Rescue" Promotion
- New Luxury Single Family Homes From $976,990 in Manalapan
- Longevityresearch.ca Unveils a Unique Bayesian Causal Atlas; Saves up to 7.9 life years/patient
- Grane Rx, a National Pharmacy Partner to PACE Programs, Names Scott Sosso President
- K2 Integrity Acquires RiskFront AI to Deliver AI Automation for Financial Crime Compliance and Risk Operations